US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US20040049014A1
(en)
*
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
EP0695189B1
(de)
*
|
1992-12-29 |
1998-11-25 |
Genentech, Inc. |
Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
|
US20030059428A1
(en)
*
|
1993-02-26 |
2003-03-27 |
Boris Skurkovich |
Treatment of autoimmune diseases
|
US20030228310A1
(en)
*
|
1996-12-23 |
2003-12-11 |
Advanced Biotherapy, Inc. |
Treatment of skin diseases
|
US20030223995A1
(en)
*
|
1996-12-23 |
2003-12-04 |
Advanced Biotherapy, Inc. |
Treatment of pemphigus vulgaris
|
US20030086925A1
(en)
*
|
1996-12-23 |
2003-05-08 |
Advanced Biotherapy, Inc. |
Treatment of autoimmune diseases
|
ATE293994T1
(de)
*
|
1997-12-01 |
2005-05-15 |
Fang Fang |
Multivalente rekombinante antikörper zur behandlung von hrv infektionen
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
CA2352572C
(en)
*
|
1998-12-01 |
2010-04-20 |
Protein Design Labs, Inc. |
Humanized antibodies to gamma-interferon
|
ES2251248T3
(es)
*
|
1998-12-09 |
2006-04-16 |
Protein Design Labs, Inc. |
Uso de anticuerpos contra il-12 para tratar la psoriasis.
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US7087726B2
(en)
*
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
WO2003062370A2
(en)
|
2001-07-19 |
2003-07-31 |
Perlan Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
PT2279753E
(pt)
|
2001-10-10 |
2016-01-15 |
Novo Nordisk As |
Remodelação e glicoconjugação de péptidos
|
DK2279755T3
(da)
|
2001-10-10 |
2014-05-26 |
Ratiopharm Gmbh |
Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
|
US7244592B2
(en)
*
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
ES2330211T3
(es)
|
2002-03-15 |
2009-12-07 |
Schering Corporation |
Metodo para modular los receptores cd200.
|
WO2003097082A2
(en)
|
2002-05-17 |
2003-11-27 |
Protein Design Labs |
Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
|
US20050019323A1
(en)
*
|
2002-05-22 |
2005-01-27 |
Protein Design Labs, Inc. |
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
|
US20040052791A1
(en)
*
|
2002-05-22 |
2004-03-18 |
Rolf Ehrhardt |
Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
|
US20040052790A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Advanced Biotherapy, Inc. |
Treatment of schizophrenia
|
US7365168B2
(en)
*
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
CA2502668C
(en)
*
|
2002-10-17 |
2013-07-30 |
Amgen Inc. |
Fully human antibody fab fragments with human interferon-gamma neutralizing activity
|
WO2004041862A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
MXPA05006853A
(es)
|
2002-12-23 |
2005-08-16 |
Schering Corp |
Usos de citocinas de mamifero; reactivos relacionados.
|
MXPA05009717A
(es)
|
2003-03-10 |
2005-10-18 |
Schering Corp |
Usos de agonistas y antagonistas de interleucina-23; reactivos relacionados.
|
JP4685764B2
(ja)
*
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
JP2007531707A
(ja)
*
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
NZ549040A
(en)
|
2004-02-17 |
2009-07-31 |
Schering Corp |
Use for interleukin-33 (IL33) and the IL-33 receptor complex
|
EP2394662B1
(de)
|
2004-04-02 |
2018-03-21 |
The Regents of The University of California |
Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20050276806A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of autism
|
TWI363091B
(en)
|
2004-12-20 |
2012-05-01 |
Schering Corp |
Uses of mammalian cytokine; related reagents
|
EP1841455A1
(de)
*
|
2005-01-24 |
2007-10-10 |
Amgen Inc. |
Humanisierter anti-amyloid-antikörper
|
WO2006109191A2
(en)
|
2005-01-27 |
2006-10-19 |
Novimmune S.A. |
Human anti-interferon gamma antibodies and methods of use thereof
|
EP3050963B1
(de)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
ES2333260T3
(es)
|
2005-09-01 |
2010-02-18 |
Schering Corporation |
Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
|
WO2007053524A2
(en)
*
|
2005-10-28 |
2007-05-10 |
The Florida International University Board Of Trustees |
Horse: human chimeric antibodies
|
AU2007232873B2
(en)
*
|
2006-03-31 |
2014-02-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
JP5406027B2
(ja)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3特異的抗体およびその使用
|
PT2059535E
(pt)
|
2006-08-18 |
2014-01-29 |
Novartis Ag |
Anticorpos específicos do prlr e suas utulizações
|
US7829674B2
(en)
|
2006-10-27 |
2010-11-09 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
EP2083862A4
(de)
*
|
2006-10-27 |
2012-09-19 |
Lpath Inc |
Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und -leiden
|
EP2101816B1
(de)
|
2006-12-07 |
2013-08-14 |
Novartis AG |
Antagonistische antikörper gegen ephb3
|
PE20090722A1
(es)
*
|
2007-02-02 |
2009-07-13 |
Amgen Inc |
Hepcidina, antagonistas de la hepcidina y metodos de uso
|
US20100135998A1
(en)
|
2007-02-28 |
2010-06-03 |
Schering Corporation |
Combination therapy for treatment of immune disorders
|
DK2164992T3
(en)
*
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
PL2158315T3
(pl)
|
2007-06-25 |
2016-10-31 |
|
Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
KR102339457B1
(ko)
|
2007-09-26 |
2021-12-14 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
WO2009072604A1
(ja)
*
|
2007-12-05 |
2009-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
抗nr10抗体、およびその利用
|
CA2709354C
(en)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
SI2275443T1
(sl)
|
2008-04-11 |
2016-03-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-vezavna molekula, ki se je sposobna ponovljivo vezati na dve ali več antigenskih molekul
|
JP2011519279A
(ja)
|
2008-05-01 |
2011-07-07 |
アムジエン・インコーポレーテツド |
抗ヘプシジン抗体及び使用の方法
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
BRPI0920582A2
(pt)
*
|
2008-10-16 |
2019-08-27 |
Cytonics Corp |
biomarcadores e métodos de detecção e tratamento da dor espinhal e de articulação
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010065921A2
(en)
*
|
2008-12-05 |
2010-06-10 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
EP2400981A4
(de)
*
|
2009-02-26 |
2013-02-27 |
Lpath Inc |
Desgin für humanisierten thrombozytenaktivierungsfaktor-antikörper mittels anti-lipid-antikörper-templates
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP2419446A4
(de)
*
|
2009-04-17 |
2013-01-23 |
Lpath Inc |
Humanisierte antikörperzusammensetzungen und verfahren zur bindung von lysophosphatidsäure
|
TW201041595A
(en)
|
2009-05-15 |
2010-12-01 |
Chugai Pharmaceutical Co Ltd |
Anti-axl antibody
|
CA2767409C
(en)
|
2009-07-24 |
2018-10-30 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
|
JP5898617B2
(ja)
|
2009-07-31 |
2016-04-06 |
メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. |
Btlaに対する完全ヒト抗体
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
PL2529033T3
(pl)
|
2010-01-26 |
2017-10-31 |
Nat Jewish Health |
Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnych
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
EP2543730B1
(de)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Variante einer konstanten antikörperregion
|
EP2621527A4
(de)
|
2010-10-01 |
2015-12-09 |
Univ Pennsylvania |
Verwendung von listerien-impfstoffvektoren zur umkehrung einer impfstoff-unempfänglichkeit bei patienten mit parasiteninfektionen
|
TR201802772T4
(tr)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
AU2012229218B2
(en)
|
2011-03-11 |
2017-03-02 |
Advaxis, Inc. |
Listeria-based adjuvants
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
BR112014012607A2
(pt)
|
2011-11-23 |
2017-06-20 |
Amgen Inc |
métodos de tratamento usando um inibidor de interferon gama
|
SG10201700392UA
(en)
|
2012-03-12 |
2017-03-30 |
Advaxis Inc |
Suppressor cell function inhibition following listeria vaccine treatment
|
ES2817897T3
(es)
|
2012-07-23 |
2021-04-08 |
La Jolla Inst Allergy & Immunology |
PTPRS y proteoglicanos en enfermedad autoinmune
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
US9969804B2
(en)
|
2013-04-01 |
2018-05-15 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin
|
JP6586087B2
(ja)
|
2013-08-20 |
2019-10-02 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
MX2016002643A
(es)
|
2013-08-29 |
2016-10-04 |
|
Conjugados de penetracion celular y metodos de uso de estos.
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP3084003A4
(de)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma-gensignaturbiomarker der tumorreaktion auf pd-1 antagonisten
|
KR20160108568A
(ko)
|
2014-02-04 |
2016-09-19 |
인사이트 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
|
PT3498734T
(pt)
|
2014-02-04 |
2021-12-06 |
Pfizer |
Combinação de um antagonista da pd-1 e um inibidor do vegfr para tratamento de cancro
|
AU2015264528A1
(en)
|
2014-05-21 |
2016-11-03 |
Kyowa Hakko Kirin Co., Ltd. |
Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
MA40475A
(fr)
|
2014-08-19 |
2017-06-28 |
Fayadat Dilman Laurence |
Anticorps anti-tigit
|
CA2955676A1
(en)
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
EP3981794A1
(de)
|
2014-12-19 |
2022-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5-antikörper und verfahren zur verwendung
|
KR20180054923A
(ko)
|
2014-12-19 |
2018-05-24 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
EP3244907B1
(de)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Peptid-linkermasken mit ctla4-bindenden proteinen
|
AR103428A1
(es)
|
2015-01-16 |
2017-05-10 |
Hope City |
Anticuerpos de penetración celular
|
US9969800B2
(en)
|
2015-02-05 |
2018-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
IL-8 antibodies
|
MX2017010858A
(es)
|
2015-02-27 |
2017-12-11 |
Chugai Pharmaceutical Co Ltd |
Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
JP6951248B2
(ja)
|
2015-03-04 |
2021-10-20 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がんを治療するための、pd−1アンタゴニスト及びエリブリンの組合せ
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
US11091543B2
(en)
|
2015-05-07 |
2021-08-17 |
Swedish Orphan Biovitrum Ag |
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
EA037532B1
(ru)
|
2015-05-07 |
2021-04-08 |
Новиммун Са |
Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
WO2016196173A1
(en)
|
2015-05-29 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
|
CN114306627A
(zh)
|
2015-08-06 |
2022-04-12 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
CA2997179A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The Unversity Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
US20190119259A1
(en)
|
2015-12-10 |
2019-04-25 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
JP6847958B2
(ja)
|
2015-12-24 |
2021-03-24 |
コーバス・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
US11649262B2
(en)
|
2015-12-28 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
US10053515B2
(en)
|
2016-01-22 |
2018-08-21 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor XI antibodies
|
KR20180103150A
(ko)
|
2016-01-25 |
2018-09-18 |
화이자 인코포레이티드 |
암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
|
SG11201807936VA
(en)
|
2016-03-14 |
2018-10-30 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
WO2017184562A1
(en)
|
2016-04-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Cmv neutralizing antigen binding proteins
|
CA3172367A1
(en)
|
2016-06-14 |
2017-12-21 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor xi antibodies
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
TWI693940B
(zh)
|
2016-08-05 |
2020-05-21 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
CA3040465A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
CN110167593A
(zh)
*
|
2016-10-24 |
2019-08-23 |
诺夫免疫股份有限公司 |
用于治疗或预防干扰素-γ相关适应症的方法、组合物和给药方案
|
AU2017348365A1
(en)
|
2016-10-28 |
2019-05-23 |
Astute Medical, Inc. |
Use of antibodies to TIMP-2 for the improvement of renal function
|
WO2018089967A1
(en)
|
2016-11-14 |
2018-05-17 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
CA3058134A1
(en)
|
2017-04-13 |
2018-10-18 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
EP3618871A4
(de)
|
2017-05-02 |
2021-01-06 |
Merck Sharp & Dohme Corp. |
Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2019025299A1
(en)
|
2017-07-31 |
2019-02-07 |
F. Hoffmann-La Roche Ag |
METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
BR112020009759A8
(pt)
|
2017-11-17 |
2023-01-31 |
Merck Sharp & Dohme |
Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
JP7376564B2
(ja)
|
2018-06-29 |
2023-11-08 |
シティ・オブ・ホープ |
特定の自己免疫疾患を治療するためのcd6標的キメラ抗原受容体
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
US20210393740A1
(en)
|
2018-09-19 |
2021-12-23 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
AU2019401575A1
(en)
|
2018-12-18 |
2021-06-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, GDF8 and Activin A
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
SG11202111262XA
(en)
|
2019-05-13 |
2021-11-29 |
Regeneron Pharma |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
CA3141531A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
JP2022533833A
(ja)
|
2019-05-24 |
2022-07-26 |
ファイザー・インク |
Cdk阻害剤を使用した組合せ療法
|
MX2021015156A
(es)
|
2019-06-11 |
2022-01-18 |
Regeneron Pharma |
Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
|
TW202137984A
(zh)
|
2019-10-29 |
2021-10-16 |
日商衛材R&D企管股份有限公司 |
用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
|
WO2021138454A1
(en)
|
2019-12-30 |
2021-07-08 |
City Of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
CA3174908A1
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
CN115996951A
(zh)
|
2020-04-30 |
2023-04-21 |
赛罗帕私人有限公司 |
抗cd103抗体
|
US20230192878A1
(en)
|
2020-05-13 |
2023-06-22 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
WO2021262791A1
(en)
|
2020-06-25 |
2021-12-30 |
Merck Sharp & Dohme Corp. |
High affinity antibodies targeting tau phosphorylated at serine 413
|
WO2022003554A1
(en)
|
2020-07-01 |
2022-01-06 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
US20230303654A1
(en)
|
2020-08-11 |
2023-09-28 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
EP4208482A1
(de)
|
2020-09-02 |
2023-07-12 |
Pharmabcine Inc. |
Kombinationstherapie aus einem pd-1-antagonisten und einem antagonisten für vegfr-2 zur behandlung von patienten mit krebs
|
WO2022053990A1
(en)
|
2020-09-14 |
2022-03-17 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
US20230365692A1
(en)
|
2020-09-24 |
2023-11-16 |
Merck Sharp & Dohme Llc |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
US20220251205A1
(en)
|
2021-01-29 |
2022-08-11 |
Merck Sharp & Dohme Corp. |
Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
|
CN112794903B
(zh)
*
|
2021-04-14 |
2021-06-25 |
广州市雷德生物科技有限公司 |
一种特异性结合IFN-γ的抗体及其应用
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|